There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
Health.com6h
Ozempic May Be Linked to Cause of Sudden Blindness, Another Study Shows
Semaglutide, the active ingredient in Ozempic and Wegovy, has been linked to a condition that can cause permanent vision loss ...
Hosted on MSN6h
Why "Hims and Hers" Stock Plummeted
The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight ...
Everyday Health7h
FDA Says Shortages of GLP-1 Drugs Mounjaro and Zepbound Are Over
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
New Scientist9h
We'll learn about Ozempic's potential for Alzheimer's disease in 2025
Two later-stage trials investigating semaglutide, the drug in Ozempic, for treating Alzheimer's disease are due to complete ...
WW International Needs To Go On A Debt Reduction Diet To Survive
Financial analyst assesses the credit market concerns and declining operating results for WW International, with insight on ...
studyfinds14h
Weight loss drugs help with fat loss – but they cause bone and muscle loss too
Explore the world of weight loss drugs. Find out how GLP-1-based drugs can lead to significant weight loss, but also bone and ...
Why are people microdosing Ozempic?
Tiny doses of the weight-loss drug can sidestep its unpleasant side effects, say influencers. But is customising the dose a ...
The American Journal of Managed Care15h
Top 5 Most-Read Heart Failure Articles of 2024
Some of the top heart failure research looked at statins and semaglutide for heart failure with preserved ejection fraction, ...
Are berberine supplements actually ‘nature’s Ozempic’? Here’s what experts have to say.
Users on TikTok have touted the benefits of taking berberine supplements, claiming benefits for weight loss, heart health and more. Do you need them?
Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health’s analysts said ...
Novo Nordisk's 27% drop was market overreaction, analysts say
Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...